The ExTINGUISH Trial of Inebilizumab in NMDAR EncephalitisResearch Question:
Does the drug, Inebilizumab, improve disability in patients with a particular type
of encephalitis, call anti-N-methly-D-aspartate receptor encephalitis?
Basic Study Information
Purpose:Location: University of Rochester
Determine the difference in disability at 16 weeks in participants with
anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line"
immunomodulatory therapies provided as standard-of-care, and either inebilizumab
(investigational agent) or placebo.
1. Diagnosis of NMDAR encephalitis
2. Age ≥ 18 years
3. Change in mental status
Study Reference #: STUDY00006222
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Christine Anne
Phone: (585) 276-3037
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search